Press release from Companies

Publicerat: 2020-01-23 08:30:00

ODI Pharma AB: The trade in ODI Pharma AB"s shares on Spotlight Stock Market commences today

Today, the 23rd of January 2020, marks the first day of trading in ODI Pharma AB"s ("ODI Pharma" or "Company") shares on Spotlight Stock Market. The share is traded under the ticker "ODI" and the ISIN code of the share is SE0013409760.

New share issue prior to listing

In the end of December 2019, ODI Pharma completed a new share issue that provided the Company with approximately SEK 25 million before issue costs. In addition to the capital, the new share issue added approximately 1,360 new shareholders to the Company. The proceeds received through the new share issue are intended to finance the Company"s operations on the Polish market.

Financial and legal advisor

Sedermera Fondkommission acted as the financial advisor and Markets & Corporate Law Nordic AB as the legal advisor in the new share issue and the listing on Spotlight Stock Market.

For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB

E-mail: info@odipharma.com

For more information regarding the new share issue and listing, please contact:

Sedermera Fondkommission

Phone: +46 40 615 14 10

E-mail: info@sedermera.se

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.

Läs mer hos Cision
Läs mer om ODI Pharma AB